Revenue
2018
2019
2020
2021
2022
2023
2024
2025
Precision Biosciences Inc (DTIL)
Price$7.47Cached quote
Net income
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $34.3M | $68.7M | $48.7M | $25.1M | $115.5M | $24.3M | $22.2M | $10.9M |
| Research & development | $54.2M | $59.6M | $53.4M | $46.1M | $115.2M | $98.1M | $82.4M | $45.1M |
| Operating expenses | $86.4M | $94.9M | $92.5M | $87.4M | $154.9M | $134.1M | $109.4M | $58.8M |
| Operating income | −$52.1M | −$26.2M | −$43.7M | −$62.3M | −$39.4M | −$109.8M | −$87.2M | −$47.9M |
| Operating margin | −152.19% | −38.08% | −89.76% | −248.26% | −34.08% | −452.25% | −392.14% | −440.25% |
| EBITDA | −$50.7M | −$22.8M | −$36.9M | −$54.5M | −$30.4M | −$101.1M | −$81.9M | −$45.6M |
| EBITDA margin | −147.91% | −33.13% | −75.77% | −217.19% | −26.31% | −416.10% | −368.23% | −418.62% |
| Net income | −$45.7M | $7.2M | −$61.3M | −$111.6M | −$30.6M | −$109.0M | −$92.9M | −$46.0M |
| Net profit margin | −133.45% | 10.43% | −125.84% | −444.80% | −26.49% | −448.86% | −417.65% | −423.02% |
| Basic EPSper basic share | -$3.56 | $1.05 | -$15.96 | -$38.10 | -$0.52 | -$2.09 | -$2.21 | -$2.92 |
| Diluted EPSper diluted share | -$3.56 | $1.04 | -$15.96 | -$38.10 | -$0.52 | -$2.09 | -$2.21 | -$2.92 |
Owners
Reported shareholders
8.44%of listed shares
Aberdeen Group plc2.23M shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
Aberdeen Group plc | 8.44%2.23M shares |
Bleichroeder LP | 7.63%2.02M shares |
Octagon Capital Advisors LP | 5.11%1.35M shares |
BOOTHBAY FUND MANAGEMENT, LLC | 5.09%1.35M shares |
BlackRock, Inc. | 4.44%1.17M shares |
VANGUARD CAPITAL MANAGEMENT LLC | 4.22%1.12M shares |
Lynx1 Capital Management LP | 3.60%950.47K shares |
Driehaus Capital Management LLC | 3.58%946.71K shares |
Empery Asset Management, LP | 2.94%776.09K shares |
Affinity Asset Advisors, LLC | 2.45%646.58K shares |
GEODE CAPITAL MANAGEMENT, LLC | 2.35%620.98K shares |
MACKENZIE FINANCIAL CORP | 1.82%481K shares |
STATE STREET CORP | 1.62%427.33K shares |
ACADIAN ASSET MANAGEMENT LLC | 1.16%305.76K shares |
ArrowMark Colorado Holdings LLC | 1.04%274.14K shares |
Corient Private Wealth LP | 0.93%245.06K shares |
Amoroso Michael | ≈0.92%243.39K shares |
TWO SIGMA INVESTMENTS, LP | 0.90%237.86K shares |
NORTHERN TRUST CORP | 0.72%190.19K shares |
JPMORGAN CHASE & CO | 0.68%180.45K shares |
Percentages use 26.43M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Feb 18, 2026Form 4 · 10b5-1 | Amoroso MichaelPresident and CEO | SellCommon Stock | 20.6K | $3.84 | $78.9K | 243.4K |
| Feb 18, 2026Form 4 · 10b5-1 | Kelly John AlexanderChief Financial Officer | SellCommon Stock | 8.1K | $3.84 | $31.3K | 125.9K |
| Feb 18, 2026Form 4 · 10b5-1 | Scimeca DarioGeneral Counsel and Secretary | SellCommon Stock | 4.9K | $3.84 | $18.9K | 56.5K |
| Feb 18, 2026Form 4 · 10b5-1 | SMITH J. JEFFERSONChief Research Officer | SellCommon Stock | 4.9K | $3.84 | $18.9K | 121.9K |
| Jan 22, 2026Form 4 · 10b5-1 | Amoroso MichaelPresident and CEO | SellCommon Stock | 34.8K | $4.17 | $145.1K | 196.2K |